This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00268476
Recruitment Status : Active, not recruiting
First Posted : December 22, 2005
Last Update Posted : April 18, 2023
Sponsor:
Information provided by (Responsible Party):
Medical Research Council

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer. This trial aims to see if we can improve the way in which prostate cancer is currently managed, either by adding new treatments to the standard approach or by modifying the type of hormone therapy aiming to improve quality-of-life by reducing the side effects of treatment. Each new treatment approach is compared against a control arm receiving the current standard treatments. We aim to identify treatment strategies that enable men to live longer, or as long but with an improved quality-of-life, as well as offering value for money for the health service.

Since opening to accrual in Oct-2005, the trial has tested many ways of treating prostate cancer and some results are now already known. More than 10,000 men will join the trial with answers becoming available throughout the trial. New patients joining the trial from Protocol version 17.0 onwards (activated in December 2018) may be eligible to join one of two treatment comparisons, metformin (treatment group K; the "metformin comparison") and transdermal oestradiol (treatment group L; the "transdermal oestradiol comparison"). A computer program will be used to allocate which treatment each participant receives, using a chance process.

Summary of the research arms in STAMPEDE trial platform Summary of research treatment groups currently open to recruitment (June 2017)

  1. Metformin (Arm K): This anti-diabetic medication is proposed to have both anti-cancer effects and may help prevent the adverse metabolic effects of long-term ADT. STAMPEDE will investigate whether adding metformin to the current standard-of-care for non-diabetic men can improve all-cause survival.
  2. Transdermal oestradiol (Arm L): This is an alternative form of hormone treatment which has been shown to suppress testosterone as effectively as standard ADT and avoid some of the side-effects. It may also help to avoid the adverse metabolic effects and fatigue and therefore improve overall quality of life compared with standard forms of ADT. STAMPEDE will investigate whether transdermal oestradiol can treat the cancer as well as current standard forms of ADT.
  3. Control group (Arm A): Patients allocated to this group receive the current standard-of-care ADT +/- RT +/- docetaxel.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Celecoxib Drug: Docetaxel Drug: Prednisolone Drug: ADT Drug: Zoledronic Acid Drug: Abiraterone Radiation: Radiotherapy to the prostate Drug: Enzalutamide Drug: Metformin Drug: Transdermal Oestradiol Phase 2 Phase 3

Detailed Description:

STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-naïve prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control arm. When the trial originally opened in 2005 there were 6 research arms enabling 5 randomised comparisons. Each comparison is evaluated in stages with pre-planned interim analyses after which recruitment may be halted should the experimental treatment fail to reach a "hurdle" of activity. Patient data from all arms and all stages are, however, included in the final analyses of the primary outcome measure, even if the investigational arm did not proceed to the final stage.

Providing sufficient activity is demonstrated, recruitment continues to the final stage and then an assessment of efficacy is determined based on the primary outcome of overall survival. Patient data from all arms and all stages are included in the final analyses of the primary outcome measure, even if the investigational arm did not proceed to the final stage.

The original comparisons which have all now been reported, evaluated a bisphosphonate (zoledronic acid), a cytotoxic chemotherapeutic agent (docetaxel) and a cyclooxygenase (Cox 2) inhibitor (celecoxib), as single agents or combinations. Since the start of the trial, a number of new research arms have been added to STAMPEDE over time to evaluate: abiraterone, a steroid synthesis inhibitor; prostate radiotherapy for patients with newly diagnosed metastatic disease; enzalutamide, an inhibitor of androgen receptor signalling, given with abiraterone; and metformin, an anti-diabetic medication and transdermal oestradiol, to be given as an alternative form of ADT.

Objectives:

Primary

To compare the safety and efficacy of novel therapeutic strategies against the current standard-of-care for men with high-risk locally advanced or metastatic prostate cancer starting long-term ADT for the first time.

Outline: This is a randomised, controlled, multi-centre MAMS trial platform. Patients are current randomised to 1 of 3 arms: control group (arm A), metformin treatment group (arm K) and transdermal oestradiol (Arm L). The other arms are all closed to recruitment with results known for all the original comparisons and awaited for others added since the trial commenced.

Patient population: STAMPEDE recruits both men with high-risk locally advanced prostate cancer and men with metastatic prostate cancer, all of whom must be starting long-term ADT for the first time. Patients who received previous radical treatment and are now relapsing with high-risk features are also eligible.

Follow-up: All patients are follow-up life long

Sub-studies: There are several translational sub-studies ongoing as part of STAMPEDE. Participation is optional. These currently include several translational sub-studies involving sample collection: saliva collection for germline DNA analysis, sequential circulating tumour DNA analysis and FFPE tumour block retrieval for DNA and RNA analysis. Other sub-studies include a QOL sub-study and an imaging sub-study.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11992 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-arm Multi-Stage
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial
Actual Study Start Date : July 8, 2005
Estimated Primary Completion Date : March 2026
Estimated Study Completion Date : December 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm A: Standard of Care
Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]
 Drug: ADT
Other Name: Androgen Deprivation Therapy
Experimental: Arm B: Zoledronic Acid
(ADT + zoledronic acid) NO LONGER RECRUITING
 Drug: ADT
Other Name: Androgen Deprivation Therapy

Drug: Zoledronic Acid
Other Name: Zometa
Experimental: Arm C: Docetaxel
(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
 Drug: Docetaxel
Other Name: Taxotere

Drug: Prednisolone
Other Name: Prednisone

Drug: ADT
Other Name: Androgen Deprivation Therapy
Experimental: Arm D: Celecoxib
(ADT + celecoxib) NO LONGER RECRUITING
 Drug: Celecoxib
Other Name: Celebrex

Drug: ADT
Other Name: Androgen Deprivation Therapy
Experimental: Arm E: Zoledronic Acid & Docetaxel
(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
 Drug: Docetaxel
Other Name: Taxotere

Drug: Prednisolone
Other Name: Prednisone

Drug: ADT
Other Name: Androgen Deprivation Therapy

Drug: Zoledronic Acid
Other Name: Zometa
Experimental: Arm F: Zoledronic Acid & Celecoxib
(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
 Drug: Celecoxib
Other Name: Celebrex

Drug: ADT
Other Name: Androgen Deprivation Therapy

Drug: Zoledronic Acid
Other Name: Zometa
Experimental: Arm G: Abiraterone
(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
 Drug: Prednisolone
Other Name: Prednisone

Drug: ADT
Other Name: Androgen Deprivation Therapy

Drug: Abiraterone
Other Name: Zytiga
Experimental: Arm H: M1 RT
(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
 Drug: ADT
Other Name: Androgen Deprivation Therapy

Radiation: Radiotherapy to the prostate
Other Name: RT
Experimental: Arm J: Abiraterone * Enzalutamide
(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
 Drug: Prednisolone
Other Name: Prednisone

Drug: ADT
Other Name: Androgen Deprivation Therapy

Drug: Abiraterone
Other Name: Zytiga

Drug: Enzalutamide
Other Name: Xtandi
Experimental: Arm K: Metformin
(ADT + Metformin) RECRUITING IN SELECTED SITES
 Drug: ADT
Other Name: Androgen Deprivation Therapy

Drug: Metformin
Other Name: Metformin Hydrochloride
Experimental: Arm L: tE2
(Transdermal oestradiol) RECRUITING
 Drug: Transdermal Oestradiol
Other Name: Progynova TS


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall survival [ Time Frame: 1:Not applicable ]
    Time to mortality


Secondary Outcome Measures :
  1. Failure-free survival [ Time Frame: 1:Not applicable ]
    Report of time from initiation of treatment to the first progression event of each patient

  2. Cost effectiveness by EuroQol [ Time Frame: 1:Not applicable ]
    Reporting the comparison of costs associated with the additional treatments provided and the survival gain attributed to the additional treatments, to SOC alone.

  3. Quality of life (QOL) by EORTC QOL Questionnaire C30 and prostate specific 25-item [ Time Frame: 1:Not applicable ]
    Determination of changes in quality of life with interventions

  4. Number of participants with treatment-related side effects as assessed by CTCAE v4.0 [ Time Frame: 1:Not applicable ]
    Reporting the incidence, type and severity of side effects within the trial population. CTCAE v4.0 will be used to classify the events names and severity.

  5. Skeletal related events [ Time Frame: 1:Not applicable ]
    Reporting the incidence and types of skeletal related events

  6. Biochemical failure [ Time Frame: 1:Not applicable ]

    For the purposes of the STAMPEDE trial, a unique threshold PSA value for biochemical failure is calculated for each patient, referred to as the PSA progression value.

    A. If PSA nadir in the 24 weeks following randomisation is more than 4ng/ml and more than 50% of the pre-treatment PSA level - immediate treatment failure.

    B. If PSA nadir in the 24 weeks following randomisation is less than or equal to 50% of the pre-treatment PSA level but remains above 4ng/ml - treatment failure will be defined as a rise of 50% above the nadir level.

    C. If PSA nadir in the 24 weeks following randomisation is less than or equal to 4ng/ml - treatment failure will be defined as at least 50% rise above the nadir value and also above 4ng/ml.


  7. Progression-free survival [ Time Frame: 1:Not applicable ]
    Reporting the incidence of mortality without a progression event

  8. Lymph node progression [ Time Frame: 1:Not applicable ]
    Reporting the incidence and severity of lymph node events

  9. Distant metastases [ Time Frame: 1:Not applicable ]
    Reporting the incidence and severity of distant metastatic events

  10. Treatment for progression [ Time Frame: 1:Not applicable ]
    Identifying and reporting the treatments used in second line treatment. Incidence and types of treatments.

  11. Disease-specific survival [ Time Frame: 1:Not applicable ]
    Reporting the mortality attributed to Prostate Cancer

  12. Non-prostate cancer death [ Time Frame: 1:Not applicable ]
    Reporting the mortality not attributed to Prostate Cancer

  13. Metabolic effects [ Time Frame: 1:Not applicable ]
    Reporting the incidence and severity of effects on metabolic systems


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 120 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria Participants must fulfil all the criteria in one of the following three categories. Additionally, all patients must fulfil the criteria in Section 4.

  1. High-Risk Newly-Diagnosed Non-Metastatic Node-Negative (N0/Nx) Disease

    Both:

    • At least two of: T category T3/4, PSA≥40ng/ml or Gleason sum score 8-10

    • Intention to treat with radical radiotherapy (unless there is a contra-indication)

    OR

  2. Newly-Diagnosed Metastatic Or Node-Positive Disease

    At least one of:

    • Stage Tany N+ M0
    • Stage Tany Nany M+

    OR

  3. Previously Radically Treated, Now Relapsing (Prior Radical Surgery And/or Radiotherapy)

    At least one of:

    • PSA ≥4ng/ml and rising with doubling time less than 6 months

    • PSA ≥20ng/ml

    • N+

    • M+

    AND

  4. General Inclusion Criteria Required For All Participants
  1. Histologically confirmed prostate adenocarcinoma
  2. Intention to treat with long-term androgen deprivation therapy
  3. Fit for all protocol treatment and follow up, WHO performance status 0-2
  4. Have completed the appropriate investigations prior to randomisation
  5. Adequate haematological function: neutrophil count ≥1.5x109/l and platelets ≥100x109/l
  6. Adequate renal function, defined as GFR ≥30ml/min/1.73m2
  7. Written informed consent
  8. Willing and expected to comply with follow up schedule
  9. Using effective contraceptive method if applicable
  1. Medical contraindications to the trial medications are given in Section 6
  2. For WHO performance status definitions see Appendix A

5. General Exclusion Criteria

Patients must not fulfil any of the criteria below:

  1. Prior systemic therapy for locally-advanced or metastatic prostate cancer (1) (except as listed in the protocol section 4.3)
  2. Prior exposure to hormone therapy for a duration of > 12 months, or prior exposure completing < 12 months before randomisation (see section 4.3.1 for permitted prior exposure details)
  3. Metastatic brain disease or leptomeningeal disease

  4. Abnormal liver functions consisting of any of the following:

    • Serum bilirubin ≥1.5 x ULN (except for patients with Gilbert's disease, for whom the upper limit of serum bilirubin is 51.3μmol/l or 3mg/dl)

    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 x ULN - site must indicate at randomisation whether one or both tests are performed at site. Where both results are available both must confirm eligibility.

  5. Any other previous or current malignant disease which, in the judgement of the responsible clinician, is likely to interfere with STAMPEDE treatment or assessment
  6. Any surgical wound (e.g. TURP) which in the judgement of the responsible clinician may interfere with or be exacerbated by protocol treatment

  7. Participant with significant cardiovascular disease, including:

    • Severe/unstable angina

    • Myocardial infarction less than 6 months prior to randomisation

    • Arterial thrombotic events less than 6 months prior to randomisation

    • Clinically significant cardiac failure requiring treatment, defined as New York Heart Association (NYHA) class II or above (1)

    • Cerebrovascular disease (e.g. stroke or transient ischaemic episode) less than 6 months prior to randomisation

    • Any other significant cardiovascular disease that in the investigator's opinion means the participant is unfit for any of the study treatments.

      1. Excluding participants receiving docetaxel as part of SOC
      2. NYHA classifications can be found in Appendix A

6. Comparison-specific eligibility criteria

In addition to the general inclusion and exclusion criteria, the following comparison-specific eligibility criteria apply.

For Randomisation to the "Metformin Comparison"

Please note from protocol v20 only patients willing to participate in the metabolic sub study should be randomised to the metformin comparison. The sub study will be conducted in a limited number of sites, see section 4.7.4 for further information.

In addition to the general inclusion and general exclusion criteria the following comparison-specific inclusion criteria must be met to be eligible for randomisation to the "metformin comparison":

• HbA1c <48mmol/mol (equivalent to <6.5%) (1)

• Adequate renal function, defined as GFR ≥45ml/min/1.73m (except for Switzerland (2))

• No history of lactic acidosis or pre-disposing conditions

  • Not current or previous treatment with metformin
  • No contra-indications to metformin
  • No current or previous medication for treatment of diabetes
  • Willingness to join the metabolic sub study

The method used to determine glomerular filtration rate may vary according to local practice.

Equations that either estimate glomerular filtration rate (eGFR) or creatinine clearance (CrCl) may be used and the same threshold value applies. Where possible, HbA1c should be performed prior to commencing SOC docetaxel to reduce the likelihood of corticosteroid-related hyperglycaemia impacting on eligibility. All participants with abnormal baseline HbA1c (i.e. 6.5% or higher) should be informed and referred to their GP for further management.

(2) Except Switzerland, please refer to SAKK appendix for local guidance

For Randomisation To The "Transdermal Oestradiol Comparison"

In addition to the general inclusion and exclusion criteria, participants fulfilling all of the following are eligible for the "transdermal oestradiol comparison":

• ≤8 weeks of anti-androgen (AR-antagonists) use

• Maximum of 1 dose of monthly or 4-weekly LHRH agonist/antagonist

• No prior LHRH agonist injection with a stated duration of effect greater than 1 month

• ≤12 weeks since first dose of any hormone therapy

• Not had a bilateral orchidectomy

• No use of cyproterone acetate (36) prior to randomisation

• No known porphyria

  • No known history of deep vein thrombosis or pulmonary embolism confirmed radiologically
  • No known thrombophilic disorder (e.g. Protein C, Protein S, antithrombin deficiency)
  • Not yet started SOC abiraterone, enzalutamide or apalutamide
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00268476


Locations
Show Show 120 study locations
Sponsors and Collaborators
Medical Research Council
Investigators
Layout table for investigator information
Study Chair: Nicholas D. James, MD Institute of Cancer Research, United Kingdom
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:
Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND; STAMPEDE Investigators. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018 May 1;29(5):1235-1248. doi: 10.1093/annonc/mdy072.
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley DP, Douis H, Gilbert D, Gillessen S, Jones RJ, Langley RE, MacNair A, Malik Z, Mason MD, Matheson D, Millman R, Parker CC, Ritchie AWS, Rush H, Russell JM, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan JM, Parikh O, Protheroe A, Rudman S, Srihari NN, Simms M, Tanguay JS, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes MR, Parmar MKB, James ND. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019 Dec 1;30(12):1992-2003. doi: 10.1093/annonc/mdz396. Erratum In: Ann Oncol. 2020 Mar;31(3):442.

Other Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.

Layout table for additonal information
Responsible Party: Medical Research Council
ClinicalTrials.gov Identifier: NCT00268476    
Other Study ID Numbers: CDR0000455008
MRC-STAMPEDE ( Other Identifier: MRC )
EU-205102 ( Other Identifier: EU )
PR08 ( Other Identifier: MRC CTU at UCL )
ISRCTN78818544 ( Registry Identifier: ISRCTN )
2004-000193-31 ( EudraCT Number )
First Posted: December 22, 2005    Key Record Dates
Last Update Posted: April 18, 2023
Last Verified: April 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medical Research Council:
Stage III Prostate Cancer
Stage IV Prostate Cancer
Recurrent Prostate Cancer
Adenocarcinoma of the prostate
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases
Zoledronic Acid
Metformin
Prednisone
Prednisolone
Celecoxib
 Docetaxel
Estradiol
Androgens
Hypoglycemic Agents
Physiological Effects of Drugs
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal